Pharma major Lupin today said it has received final approval from the US health regulator for its anti-depression drug Imipramine Pamoate capsules.
Lupin Pharmaceuticals, the US subsidiary of Mumbai-based Lupin Ltd, has been granted final approval from the Food and Drug Administration (FDA) for the capsules in strengths of 75 mg, 100 mg, 125 mg and 150 mg.
Commercial shipments of the product have already started, Lupin Ltd said in a statement to the Bombay Stock Exchange (BSE).
The drug is recommended for relieving depression symptoms.
Lupin's Imipramine Pamoate capsules are generic equivalent of Mallinckrodt's Tofranil-PM.
The drug had an annual sales of about USD 39 million for the year ended December, 2009.
Shares of Lupin were quoting at Rs 1,672.20, higher by 1.09 per cent in afternoon trade on the BSE.